BriaCell Therapeutics Corp. announced a clinical trial collaboration and supply agreement with Incyte, a global biopharmaceutical company focused on discovering and developing novel therapeutics in oncology and other serious diseases.
The Agreement is focused on, but not limited to, the selection of novel combinations for the treatment of advanced breast cancer along with a planned clinical study of BriaCell’s lead candidate, Bria-IMT, with Incyte’s selected compounds for advanced breast cancer.
Under the terms of the Agreement, BriaCell will evaluate combinations of novel therapeutics for the treatment of patients with advanced breast cancer. Incyte will provide BriaCell with selected novel compounds to be used in the planned combination study with Bria-IMT.
“It is our belief that checkpoint inhibitors may significantly amplify the tumor-reducing effects of BriaCell’s novel immunotherapy, Bria-IMT, in advanced breast cancer patients. Incyte’s portfolio has several candidates, including an anti-PD-1 monoclonal antibody and an IDO1 inhibitor, that we hope will improve the clinical benefits of Bria-IMT,” stated Dr. Bill Williams, BriaCell’s President and Chief Executive Officer. “Incyte is a world-class biopharmaceutical company, we are aligned with the value that the team there places on innovation and we look forward to working with Incyte’s scientists and clinical experts to develop novel therapeutics for advanced breast cancer patients.”